• 1
    The Greatest threat to women's health. Lancet 2003; 362: 1165.
  • 2
    Barrett-Connor E. An epidemiologist looks at hormones and heart disease in women. J Clin Endocrinol Metab 2003; 88: 403142.
  • 3
    Oger E. Incidence of venous thromboembolism: a community-based study in western France. Thromb Haemost 2000; 83: 65760.
  • 4
    Writing Group for the Women's Health Initiative Investigators. Risk and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomised controlled trial. JAMA 2002; 288: 32133.
  • 5
    Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SA, Black H, Bonds D, Brunner R, Brzyski R, Caan B, Chlebowski R, Curb D, Gass M, Hays J, Heiss G, Hendrix S, Howard BV, Hsia J, Hubbell A, Jackson R, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomised controlled trial. JAMA 2004; 291: 170112.
  • 6
    Cushman M, Kuller LH, Prentice R, Rodabough RJ, Psaty BM, Stafford RS, Sidney S, Rosendaal FR for the Women's Health Initiative Investigators. Estrogen plus progestin and risk of venous thrombosis. JAMA 2004; 292: 157380.
  • 7
    World Health Organisation. Obesity: Preventing and Managing the Global Epidemic. Report of a WHO Consultation. Geneva: World Health Organisation, 2000 (WHO Technical Report Series, no. 894).
  • 8
    Anderson FA, Spencer FA. Risk factors for venous thromboembolism. Circulation 2003: 107: 916.
  • 9
    Heit JA, Silverstein MD, Mohr DN, Petterson TM, O'Fallon WM, Melton III LJ. Risk factors for deep vein thrombosis and pulmonary embolism. A population-based case–control study. Arch Inter Med 2000; 160: 80915.
  • 10
    Tsai AW, Cushman M, Rosamond WD, Heckbert SR, Polak JF, Folsom AR. Cardiovascular risk factors and venous thromboembolism incidence. The longitudinal investigation of thromboembolism etiology. Arch Intern Med 2002; 162: 11829.
  • 11
    Samama MM. An epidemiologic study of risk factors for deep vein thrombosis in medical outpatients: the SIRIUS Study. Arch Intern Med 2000; 160: 341520.
  • 12
    Goldhaber SZ, Grodstein F, Stampfer MJ, Manson JE, Colditz GA, Speizer FE, Willett WC, Hennekens CH. A prospective study of risk factors for pulmonary embolism in women. JAMA 1997; 277: 6425.
  • 13
    Goldhaber SZ, Savage DD, Garrison RJ, Castelli WP, Kannel WB, McNamara PM, Gherardi G, Feinleib M. Risk factors for pulmonary embolism. The Framingham Study. Am J Med 1983; 74: 10238.
  • 14
    Scarabin PY, Oger E, Plu-Bureau G. Differential association of oral and transdermal estrogen-replacement therapy with venous thromboembolism risk. Lancet 2003; 362: 42832.
  • 15
    Straczek C, Oger E, Beau Yon de Jonage-Canonico M, Plu-Bureau G, Conard J, Meyer G, Alhenc-Gelas M, Emmerich J, Lévesque H, Trillot N, Barrellier MT, Wahl D, Scarabin PY, on behalf of the Estrogen and ThromboEmbolism Risk (ESTHER) Study Group. Prothrombotic mutations, hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration. Circulation 2005; 112: 3495500.
  • 16
    Hosmer DW, Lemeshow S. Logistic regression for matched case-control studies. In: Applied Logistic Regression. Hoboken, NJ: John Wiley & Sons, 1989: 20112.
  • 17
    Jick H, Derby LE, Myers MW, Vasilakis C, Newton KM. Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens. Lancet 1996; 348: 98183.
  • 18
    Daly E, Vessey MP, Hawkins MM, Carson JL, Gough P, Marsh S. Risk of venous thromboembolism in users of hormone replacement therapy. Lancet 1996; 348: 97780.
  • 19
    Daly E, Vessey MP, Painter R, Hawkins MM. Case–control study of venous thromboembolism risk in users of hormone replacement therapy. Lancet 1996; 348: 1027.
  • 20
    Grodstein F, Stampfer MJ, Goldhaber SZ, et al. Prospective study of exogenous hormones and risk of pulmonary embolism in women. Lancet 1996; 348: 98387.
  • 21
    Perez-Gutthann S, Garcia Rodriguez LA, Castellsague J, Duque OA. Hormone replacement therapy and risk of venous thromboembolism: population based case–control study. BMJ 1997; 314: 796800.
  • 22
    Varas-Lorenzo C, Garcia-Rodriguez LA, Cattaruzzi C, Troncon MG, Agostinis L, Perez-Gutthann S. Hormone replacement therapy and the risk of hospitalization for venous thromboembolism: a population based study in southern Europe. Am J Epidemiol 1998; 147: 38790.
  • 23
    Hoibaaten E, Abdelnoor M, Sandset PM. Hormone replacement therapy with estradiol and the risk of venous thromboembolism: a population-based case–control study. Thromb Haemost 1990; 82: 121821.
  • 24
    Smith NL, Heckbert SR, Lemaitre RN, Reiner AP, Lumley T, Weiss NS, Larson EB, Rosendaal FR, Psaty BM. Esterified estrogens and conjugated equine estrogens and the risk of venous thrombosis. JAMA 2004: 292: 15817.
  • 25
    Hulley S, Grady D, Bush T, et al. Randomised trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study Research Group. JAMA 1998; 280: 60513.
  • 26
    Abdollahi M, Cushman M, Rosendaal FR. Obesity: risk factor of venous thrombosis and interaction with coagulation factor levels and oral contraceptive use. Thromb Haemost 2003; 89: 4938.
  • 27
    Scarabin PY, Alhenc-Gelas M, Plu-Bureau G, Taisne P, Agher R, Aiach M. Effects of oral and transdermal estrogen/progesterone regimens on blood coagulation and fibrinolysis in postmenopausal women: a randomised controlled trial. Arterioscler Thromb Vasc Biol 1997; 17: 30718.
  • 28
    Vehkavaara S, Silveira A, Hakala-Ala-Pietila T, Virkamaki A, Hovatta O, Hamsten A, Taskinen MR, Yki-Jarvinen H. Effects of oral and transdermal estrogen replacement therapy on markers of coagulation, fibrinolysis, inflammation and serum lipids and lipoproteins in postmenopausal women. Thromb Haemost 2001; 85: 61925.
  • 29
    Post MS, Christella M, Thomassen LG, Van Der Mooren MJ, Van Baal WM, Rosing J, et al. Effect of oral and transdermal estrogen replacement therapy on hemostatic variables associated with venous thrombosis: a randomized, placebo-controlled study in postmenopausal women. Arterioscler Thromb Vasc Biol 2003; 23: 111621.
  • 30
    Oger E, Alhenc-Gelas M, Lacut K, Blouch MT, Roudaut N, Kerlan V, et al. Differential effects of oral and transdermal estrogen/progesterone regimens on sensitivity to activated protein C among postmenopausal women: a randomized trial. Arterioscler Thromb Vasc Biol 2003; 23: 16716.
  • 31
    Juhan-Vague I, Alessi MC, Mavri A, Morange PE. Plasminogen activator inhibitor-1, inflammation, obesity, insulin resistance and vascular risk. J Thromb Haemost 2003; 1: 15759.
  • 32
    Lisman T, De Groot P, Meijers J, Rosendaal F. Reduced plasma fibrinolytic potential is a risk factor for venous thrombosis. Blood 2005; 105: 11025.
  • 33
    Vormittag L, Vukovich T, Schonauer V, Lehr S, Minar E, Bialonczyk C, Hirschl M, Pabinger I. Basal high-sensitivity-C-reactive protein levels in patients with spontaneous venous thromboembolism. Thromb Haemost 2005; 93: 48893.
  • 34
    Douketis JD, Sharma AM. Obesity and cardiovascular disease: pathogenic mechanisms and potential benefits of weight reduction. Semin Vasc Med 2005; 5: 2533.
  • 35
    Jick H, Vessey MP. Case-control studies in the evaluation of drug-induced illness. Am J Epidemiol 1978; 107: 17.